Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You want Galencia shares?
I sold all my RLYP on open market
Very Good Question, Was wondering that myself
I'm gonna ask a stupid question, but what happens now if you didn't take the offer, or sell your shares before today?
March, and be very happy RLYP
Panzers officially cash out RLYP what a ride
Guess 32 BO fine lol
Additional RLYP bid comes this week 36-41 a share
I'm staying in for second bid
Yes - anyone short as of the date on which the deal completes will be forced to cover.
Like many on the board, I initially thought the buy out price was a little low (I was looking for $35 to $40 ps) but a 59% premium is nothing to sneeze at.
My question does not focus on another potential bidder but on the large short position that existed with this stock just before the buyout. Given the sudden increase in price, would this not create a short squeeze and potentially drive the price up in the short term, thus allowing those who expected a higher buy out price to sell their shares before the buyout is finalized? I guess my question is what happens to those people who had a short position - don't they have to cover before the buyout occurs?
Anyone who was playing the long deserves to enjoy a moment of shorts desperation. Shorts sure caused a lot of discord. The buyout price was cheap, but operating expenses to continue would not entertain a higher price tag in the short term. Having to wait for sales to catch fire so there would be adequate cash was a race that was not going to be won in time.
Many sold not knowing full house in hand
$32 was like first ante
Bidders gonna pay way more than $32
Shorts mowed down by massive panzer blitzkrieg
Looking for 50% more after Zs call next week
Let the bidding wars begin!!
Calculated greed will prevail here
Panzers continuing RLYP blitzkrieg to upper 30s
Biotech Movers: Adamas, Relypsa and Biogen
http://marketexclusive.com/biotech-movers-4/9421/?icd1
Yes we did and all out first thing this morning. Congrats lets get that other stock to fly…..some day
$32 jist the baseline trust me
JO PLAYING PERFECT HAND
BIDDING WAR JIST GETTIMG STARTED
PANZERS HOLDING FOR MORE
BOOOM GIRLFRIEND WE DID IT RLYP
Next up for RLYP shareholders:
https://biotechinvesting.info/2016/07/21/what-now-for-rlyp-shareholders/
Congrats to all longs, but now it's time to put those profits to work!
Supposedly a meeting at 10. No other details have been released that I have knowledge of for the time being.
Kill all the rumors in my opinion. If not a done deal it will cost RLYP 49 million dollars, which I do not pretend to believe that RLYP could afford without a dilution to shareholders.
Dear Colleagues,
I’m pleased to share some important news. This evening, we announced that Relypsa and Galenica have entered into a definitive agreement under which Galenica will acquire Relypsa. Galenica intends for Relypsa to become the U.S. headquarters of its Vifor Pharma Business Unit. We issued a joint press release with Galenica, which is available on our website here.
Before I share more about why I am excited about this agreement, I want to express how proud I am of the passion I have witnessed each of you bring every day as we have worked together to build our company into what it is today. These sentiments are shared by our Board and the rest of the management team.
Since I joined Relypsa, I have been humbled by the opportunity to lead this great team of people through a number of transitions: from a private to publicly-traded company; from development-stage to commercial-stage; from approximately 60 employees to more than 400 committed to bringing Veltassa and our unique science to patients. Relypsa made history with the FDA-approval of the first new medicine for hyperkalemia in more than 50 years. Delivering an innovative medicine to people in need is a privilege that few companies in our industry achieve.
Now, we will experience another transition. We have the opportunity to become part of a global company that is closely aligned in their commitment to people with cardio-renal diseases and the belief that Veltassa is an important medicine that can change the lives of patients.
As you may know, Galenica is a parent company of our ex-U.S. partner, VFMCRP, a joint company between Vifor Pharma and Fresenius Medical Care. Many of you have had the opportunity to interact with VFMCRP and know that they have been an excellent partner. Combining Relypsa with Vifor Pharma expands this relationship with the goal of creating a world-leading specialty pharmaceutical company focused on nephrology, cardiology and gastroenterology medicines.
Vifor Pharma believes Relypsa’s talented people are vital to the ongoing success of the company and a key driver of the acquisition. As such, we believe they intend to retain the vast majority of Relypsa’s employees in their current roles. They are committed to making and communicating specific plans as quickly as possible following the closing of the transaction. Longer term, I believe this acquisition will provide exciting opportunities and that it greatly enhances our ability to continue our mission of improving patients’ lives.
The proposed acquisition has been fully endorsed by our Board following an informed, thoughtful and careful process. We must now fulfil a number of other regulatory and legal conditions, including the tender of a majority of the outstanding shares of Relypsa’s common stock. We anticipate the transaction will close during the third quarter of 2016.
I know this news comes as a surprise and also late at night. I also know you will have a lot of questions. We may not be able to answer all of them right now, but we are committed to keeping you as informed as much as we are able during the coming weeks.
We will hold a Company Meeting tomorrow (Thursday) at 10am PT. A calendar invite will be sent shortly with details. We will have two important guests from Vifor Pharma joining us at the meeting, Colin Bond, CFO and Michael Puri, Global Head of HR. They are very much looking forward to meeting you all and introducing you to Vifor Pharma.
We have achieved historic milestones together and I want to thank you again for your tireless hard work and commitment to helping patients. I look forward to speaking with you all tomorrow morning.
John
Notice to Investors/Important Additional Information and Where to Find It
This communication is not a recommendation, an offer to purchase or a solicitation of an offer to sell shares of Relypsa’s common stock or other securities. Vifor Pharma USA Inc. (“Vifor Pharma”) has not commenced the tender offer (the
“Offer”) described in this communication. Upon commencement of the Offer, Galenica AG (“Galenica”) and Vifor Pharma will file with the United States Securities and Exchange Commission (the “SEC”) a Tender Offer Statement on Schedule TO and related exhibits, including the offer to purchase (the “Offer to Purchase”), letter of transmittal (the “Letter of Transmittal”), and other related documents and, thereafter, Relypsa will file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the Offer. Once filed, holders of common stock and other Relypsa securities can obtain these documents free of charge from the SEC’s website at www.sec.gov. Holders of common stock and other Relypsa securities may also obtain, at no charge, any documents filed with or furnished to the SEC by Relypsa from the “Investors” section of Relypsa’s website at http://investor.relypsa.com. THE TENDER OFFER MATERIALS (INCLUDING THE OFFER TO PURCHASE, THE RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL CONTAIN IMPORTANT INFORMATION. HOLDERS OF RELYPSA’S SECURITIES ARE ADVISED TO READ THESE DOCUMENTS AND RELATED EXHIBITS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AND PRIOR TO MAKING ANY DECISIONS WITH RESPECT TO WHETHER TO TENDER THEIR SHARES TO VIFOR PHARMA PURSUANT TO THE OFFER.
Cautionary Statement regarding Forward-Looking Statements
The statements included in this communication that are not a description of historical facts are forward-looking statements. Words or phrases such as “believe,” “may,” “could,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “seek,” “plan,” “expect,” “should,” “would” or similar expressions are intended to identify forward-looking statements and are based on Relypsa’s current beliefs and expectations. These forward-looking statements include without limitation statements regarding the planned completion of the Offer and the Merger; statements regarding the anticipated filings and approvals relating to the Offer and the merger (the “Merger”); statements regarding the expected completion of the Offer and the Merger and statements regarding the ability of Galenica to complete the Offer and the Merger considering the various closing conditions. Relypsa’s actual future results may differ materially from Relypsa’s current expectations due to the risks and uncertainties inherent in its business. These risks include, but are not limited to: uncertainties as to the timing of the Offer and the Merger; uncertainties as to the percentage of Relypsa’s stockholders tendering their shares in the Offer; the possibility that competing offers will be made; the possibility that various closing conditions to the Offer or the Merger may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the Merger; the effects of disruption caused by the transaction making it more difficult to maintain relationships with employees, collaborators, vendors and other business partners; the risk that stockholder litigation in connection with the Offer or the Merger may result in significant costs of defense, indemnification and liability; and risks and uncertainties pertaining to the business of Relypsa, including the risks and uncertainties detailed under “Risk Factors” and elsewhere in Relypsa’s public filings with the SEC, as well as the tender offer materials to be filed by Galenica and Vifor Pharma.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Relypsa undertakes no obligation to revise or update this report to reflect events or circumstances after the date hereof, except as required by law.
http://ih.advfn.com/p.php?pid=nmona&article=72020578
"Relypsa has agreed to pay Parent a termination fee of $49 million in cash upon termination of the Merger Agreement under certain specified circumstances, including in connection with a termination of the Merger Agreement by Relypsa to accept a competing transaction proposal. "
I do not see another offer feasible. RLYP cannot with stand the penalty in my opinion of 49 million dollars.
Relypsa Shareholders Upset Over Merger Bid - (via NewsPoints Desk)
July 21, 2016
Tags: NewsPoints Relypsa Galenica United States Corporate Affairs Mergers & Acquisitions
A group of Relypsa Inc. shareholders are upset with the sale of the Company for $32 per share, and are looking at options to increase the $1.5 billion purchase of the company by the Galenica Group.
The shareholders contest that the purchase price of only $32 is insufficient in light of the company's growth
prospects and that deal-protection clauses in the merger agreement preclude other companies from submitting successful competing offers. In addition, senior management of the Company obtained personal benefits for their own self interests in agreeing to sell the company for this unfairly low price to the detriment of its shareholders.
Relypsa did not immediately respond to requests for a comment.
To contact the law firm handling the matter on behalf of shareholders of Relypsa for more information call toll free 800.511.7037
Interesting, but is that because the law sharks are out hunting?
Chatter of another bid to come
I agree the $32 is a bit disappointing, but a profit is a profit.
I am glad this headache is over with.
Now will the price go higher? The short interest needs to be covered.
I can't believe this. I've been holding through thick and thin since last year. I wish BO price would've been higher, but still a decent win. Congrats long.
Major shareholders control the board, the board approved. I agree this seems low but it's a different market these days and clearly it would have been disastrous if they diluted and tried to go at it alone.
Mildly disappointing that they only got $32 a share, but I was holding 4,000 shares so a nice surprise to wake up to. Congrats to those holding.
Wow. Can't believe this buyout actually took place. These rumors were around for a while. Sold too soon.
I really don't think major shareholders will sell at 32. I could be wrong, but sounds like this is just the beginning to the end.
Wish I bought more today . Only purchase additional 100 shares.
Congrats to those who are longs.
CONGRATS all, Galencia bought Relypsa for $32 a share.
Good point. The wedge is going to have to resolve at some point.
Scripts keep growing it will halt and or slow down the cash burn. Future holds profitability. Holding breath!
Really no rhyme or reason to it other than shorts being in control. I am still of the opinion that it's MS and Bernes, as we all know hired by AZN, are there to keep it down as AZN knew they f'ed up. Maybe not even that but just to push RLYP out of the way as a competitor. Regardless the price doesn't lie as it's being held under water till it drowns under it's own weight of being to cash burn heavy. Fundamentally nothing is wrong other than the cash burn. Every single pice of good news is shorted. The wedge is going to have to resolve at some point...
I am holding RLYP but I have to think the sector downtrend is not helping this stock. Bios/pharmas are totally out of favor and have been for awhile thanks to Hilary Clinton and probably will be this way until at least the election is over…..of course there is always the chance RLYP will move up based on news…updates….buyout rumors…..etc.
But from my view all signs point to RLYP should be up from here.
In all my days I have not been involved in an approval that takes the stock for a down turn. Now that this label is being worked out and the competition has been delayed. I see little reason why the share price is not beating up new 52 week highs. The scripts will continue to gain. Some months maybe smaller than others, but the script growth is going to continue. The added bonus that blood pressures decrease with Valtessa usage is truly unremarkable.
I sure hope more posters come to IHUB. Yahoo RLYP financial board is very hard on the eyes for the time being.
OPINION
Honestly am not fazed by this stock having down days or mood swings anymore. I know what I own and she's a keeper.
Followers
|
23
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
372
|
Created
|
11/26/13
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |